Targeting c-MET activity, either with small molecule inhibitors or RNA interference, has been shown to suppress the cancer stem-like phenotype by downregulating CSC markers, including CD133, CD44, ABCG2, Sox2, and ALDH1 [53]. The gene discussed is CD44; the disease is cancer.